1. 113 Cancer cells utilize lipid metabolism under hypoxia and nutrient starvation. (September 2015) Authors: Osawa, T.; Shimamura, T.; Ayano, K.; Shibuya, M.; Kodama, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ASKP1240, a Fully Human Anti‐CD40 Monoclonal Antibody, Prolongs Pancreatic Islet Allograft Survival in Nonhuman Primates. Issue 8 (10th July 2013) Authors: Watanabe, M.; Yamashita, K.; Suzuki, T.; Kamachi, H.; Kuraya, D.; Koshizuka, Y.; Ogura, M.; Yoshida, T.; Aoyagi, T.; Fukumori, D.; Shimamura, T.; Okimura, K.; Maeta, K.; Miura, T.; Sakai, F.; Todo, S. Journal: American journal of transplantation Issue: Volume 13:Issue 8(2013) Page Start: 1976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Identification of potent small molecule allosteric inhibitors of SHP2. (October 2020) Authors: Hearn, K.; Berdini, V.; Chessari, G.; Davies, T.G.; Day, J.E.H.; Hamlett, C.; Hiscock, S.; Martins, V.; Muench, S.; Nakatsuru, Y.; Ochiiwa, H.; Price, A.; Rich, S.; Shah, A.; Shibata, Y.; Shimamura, T.; Smyth, T.; Wallis, N.G.; Wilsher, N.E.; Johnson, C.N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Surgica benefit of hepatectomy for huge Alveolar echinococcosis followed by chemotherapy. (September 2018) Authors: Kamiyama, T.; Orimo, T.; Wakayama, K.; Shimada, S.; Nagatsu, A.; Kawamura, N.; Yokoo, H.; Kamachi, H.; Shimamura, T.; Taketomi, A. Journal: HPB Issue: Volume 20(2018)Supplement 2 Page Start: S295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window. (December 2016) Authors: Irie, H.; Ito, K.; Kataoka, Y.; Fujioka, Y.; Oguchi, K.; Shimamura, T.; Kawai, Y.; Sagara, T.; Shibata, Y.; Araki, H.; Haruma, T.; Hashimoto, A.; Matsuo, K.; Utsugi, T.; Iwasawa, Y. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent inhibition for activated mutations of HER2 while sparing EGFR inhibition. (December 2016) Authors: Oguchi, K.; Irie, H.; Ito, K.; Fujioka, Y.; Yamada, Y.; Shimamura, T.; Kawai, Y.; Shibata, Y.; Araki, H.; Haruma, T.; Fujioka, A.; Sagara, T.; Matsuo, K.; Utsugi, T.; Iwasawa, Y. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗